DDInter769 DDInter1840
Fluvastatin is an antilipemic agent that competitively inhibits hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase. HMG-CoA reductase catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin belongs to a class of medications called statins and is used to reduce plasma cholesterol levels and prevent cardiovascular disease. It is also the first entirely synthetic HMG-CoA reductase inhibitor and is structurally distinct from the fungal derivatives of this therapeutic class. Fluvastatin is a racemate comprising equimolar amounts of (3R,5S)- and (3S,5R)-fluvastatin.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Fluvastatin {u} (Compound) binds {v} (Gene) CYP2C19
CYP2C19 {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} (Compound) causes {v} (Side Effect) Oedema peripheral
Oedema peripheral {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Fluvastatin {u} (Compound) downregulates {v} (Gene) CCNA2
CCNA2 {u} (Gene) is regulated by {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} (Compound) downregulates {v} (Gene) BAG3
BAG3 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} (Compound) upregulates {v} (Gene) PTPN6
PTPN6 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} (Compound) downregulates {v} (Gene) CCND1
CCND1 {u} (Gene) interacts with {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Ponatinib {u} (Compound) binds {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Pazopanib
Pazopanib {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Toremifene {u} (Compound) upregulates {v} (Gene) SRC
SRC {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Toremifene
Toremifene {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Trabectedin
Fluvastatin (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Trabectedin (Compound)
Fluvastatin (Compound) causes Oedema peripheral (Side Effect) and Oedema peripheral (Side Effect) is caused by Trabectedin (Compound)
Fluvastatin (Compound) downregulates CCNA2 (Gene) and CCNA2 (Gene) is regulated by SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin (Compound) downregulates BAG3 (Gene) and BAG3 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin (Compound) upregulates PTPN6 (Gene) and PTPN6 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin (Compound) downregulates CCND1 (Gene) and CCND1 (Gene) interacts with SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib (Compound) binds SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) upregulates SRC (Gene) and SRC (Gene) is bound by Trabectedin (Compound)
Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Trabectedin (Compound)